Skip to content

US · SRTA · MEDICAL - CARE FACILITIES

Strata Critical Medical, Inc. (SRTA) intrinsic value and stock valuation

$4.56as of 2026-11-21 · Mkt cap 506.18M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Strata Critical Medical, Inc. DCF and intrinsic value

InvestorsCraft values SRTA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from SRTA’s statements →

Strata Critical Medical, Inc. Graham Number

Graham Number: $6.18d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Care Facilities New York, NY 10001 stratacritical.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$197.1M+53.1% 5y CAGRd
20192025
Net income
$41.4M
20192025
Free cash flow
-$-59.92M
20192025
Total equity
$279.1M+90.6% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$197.1M$248.7M$225.2M$146.1M$50.5M
Operating income-$-22.35M-$-33.93M-$-68.12M-$-53.53M-$-24.09M
Net income$41.4M-$-27.31M-$-56.08M-$-27.26M-$-40.05M
EPSd$501.5K-$-352.39K-$-762.79K-$-382.65K-$-571.33K
Operating cash flow-$-48.91M-$-2.52M-$-32.35M-$-37.13M-$-15.62M
Capital expenditure-$-11.01M-$-32.99M-$-2.11M-$-730K-$-800K
Free cash flow-$-59.92M-$-35.51M-$-34.46M-$-37.86M-$-16.42M
Total assets$325.5M$256.7M$294.9M$325M$335.9M
Total debt$3.31M$9.32M$24.5M$18.3M$720K
Net debt-$-27.66M-$-9.06M-$-3.35M-$-23.01M-$-1.88M
Total equity$279.1M$221.9M$234.3M$274.5M$291.4M
Cash and short-term investments$61.2M$127.1M$166.1M$192.1M$282M
Income statement
20252024202320222021
Revenue$197.1M$248.7M$225.2M$146.1M$50.5M
Cost of revenue$156M$189.8M$183.1M$123.8M$40M
Gross profit$41.1M$58.9M$42.1M$22.3M$10.5M
Research and development expenses$3.05M$3.18M$4.63M$5.54M$1.68M
Selling, general and administrative expenses$60.9M$89.7M$105.6M$70.3M$32.9M
Other expenses-$-450K$0.00$0.00$0.00$0.00
Operating expenses$63.5M$92.8M$110.2M$75.8M$34.6M
Cost and expenses$219.5M$282.6M$293.3M$199.7M$74.6M
Interest income$4.24M$7.21M$8.44M$3.43M$460K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$6.9M$5.96M$7.11M$5.72M$600K
Ebitda-$-5.71M-$-21.6M-$-50.43M-$-22.31M-$-43.1M
Operating income-$-22.35M-$-33.93M-$-68.12M-$-53.53M-$-24.09M
Total other income/expenses, net$2.29M$6.36M$10.6M$25.5M-$-19.6M
Income before tax-$-20.07M-$-27.56M-$-57.54M-$-28.03M-$-43.7M
Income tax expense$0.00-$-260K-$-1.47M-$-770K-$-3.64M
Net income$41.4M-$-27.31M-$-56.08M-$-27.26M-$-40.05M
Weighted average shares outstanding$82.5M$77.5M$73.5M$71.2M$70.1M
Weighted average diluted shares outstanding$82.5M$77.5M$73.5M$71.2M$70.1M
Balance sheet
20252024202320222021
Cash and short-term investments$61.2M$127.1M$166.1M$192.1M$282M
Net receivables$40M$21.6M$21M$10.9M$5.55M
Inventory$0.00$0.00$0.00$0.00$550K
Total current assets$126.2M$160.7M$206.3M$218.1M$294.9M
Property, plant and equipment, net$39.6M$39.8M$26.4M$19.7M$2.76M
Goodwill and intangible assets$135.7M$54.7M$60.9M$85.8M$37.8M
Long-term investments$0.00$0.00$0.00$0.00$200K
Total non-current assets$199.3M$95.9M$88.7M$106.9M$40.9M
Total assets$325.5M$256.7M$294.9M$325M$335.9M
Accounts payable$19.1M$0.00$0.00$16.5M$6.37M
Short-term debt$650K$3.3M$4.79M$3.36M$440K
Deferred revenue$0.00$6.66M$6.84M$0.00$0.00
Total current liabilities$19.8M$22.7M$35.5M$26.6M$12.8M
Long-term debt$2.65M$6.02M$19.7M$15M$280K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$26.6M$12M$25.2M$23.9M$31.7M
Capital lease obligations$3.31M$9.32M$24.5M$18.3M$720K
Total liabilities$46.4M$34.7M$60.6M$50.5M$44.5M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-145.55M-$-186.9M-$-159.75M-$-103.68M-$-76.42M
Accumulated other comprehensive income (loss)$0.00$1.75M$3.96M$2.29M-$-900K
Total equity$279.1M$221.9M$234.3M$274.5M$291.4M
Total investments$30.3M$108.8M$138.3M$150.7M$279.6M
Total debt$3.31M$9.32M$24.5M$18.3M$720K
Net debt-$-27.66M-$-9.06M-$-3.35M-$-23.01M-$-1.88M
Cash flow statement
20252024202320222021
Net income$41.4M-$-27.31M-$-56.08M-$-27.26M-$-40.05M
Depreciation and amortization$8.19M$5.96M$7.11M$5.72M$600K
Stock-based compensation$17.8M$19.9M$12.5M$8.28M$9.62M
Change in working capital-$-9.08M-$-3.01M-$-6.74M-$-20K-$-2.2M
Accounts receivable-$-12.03M-$-1M-$-10.25M-$-5.35M-$-410K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$9.9M$0.00
Net cash provided by operating activities-$-48.91M-$-2.52M-$-32.35M-$-37.13M-$-15.62M
Investments in property, plant and equipment-$-9.6M-$-30.88M-$-2.11M-$-730K-$-300K
Acquisitions, net-$-69.34M-$-2.23M-$-40K-$-48.1M-$-23.07M
Net cash used for investing activities$69.8M-$-1.02M$17.1M$79.3M-$-321.34M
Common stock issued$190K$0.00$0.00$90K$119.6M
Common stock repurchased$0.00-$-240K$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-8.91M-$-5.76M-$-80K-$-1.08M$332.3M
Net change in cash$11.6M-$-9.37M-$-15.4M$36.8M-$-4.69M
Cash at end of period$31.2M$19.7M$29M$44.4M$7.58M
Operating cash flow-$-48.91M-$-2.52M-$-32.35M-$-37.13M-$-15.62M
Capital expenditure-$-11.01M-$-32.99M-$-2.11M-$-730K-$-800K
Free cash flow-$-59.92M-$-35.51M-$-34.46M-$-37.86M-$-16.42M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Strata Critical Medical, Inc.

        Strata Critical Medical, Inc. is dedicated to supporting healthcare providers throughout the United States by offering swift logistical management and specialized medical assistance. A significant part of their operations involves the movement of human organs for transplant, utilizing both aerial and ground transportation methods. Founded in 2014, the organization previously operated under the name Blade Air Mobility, Inc. and is set to officially change its name to Strata Critical Medical, Inc. in August of 2025. Its primary corporate office is located in New York, New York.

        CEO
        Melissa Tomkiel
        Employees
        601
        Beta
        2.22

        Explore

        Frequently asked questions

        What is the intrinsic value of Strata Critical Medical, Inc. (SRTA)?

        Strata Critical Medical, Inc. (SRTA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SRTA undervalued?

        SRTA trades at a price of $4.56 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.